| abstract |
(57) [Abstract] [Problem] Melatonin itself has a drawback that it rapidly decomposes in vivo when administered, and has low bioavailability when used for the treatment of sleep disorders and biological disorders of the biological clock. . It is an object of the present invention to develop and provide compounds that compensate for this drawback. A bicyclic amide compound, ie, a tetralinyl- or indanyl-ethylamide compound, was developed and synthesized as a melatonin-like compound. The bioassays for these compounds are stable compounds that bind to human tissue melatonin receptors with strong affinity and show excellent melatonin-like activity for the treatment of diseases related to biological clock biological disorders. It was suggested to be effective. |